- Home
- AWRE vs BCAB Comparison
AWRE vs BCAB Comparison
Compare AWRE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AWRE | BCAB |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 71.6M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AWRE | BCAB |
|---|---|---|
| Price | $2.14 | $0.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 27.5K | ★ 1.3M |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,428,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.72 | N/A |
| 52 Week Low | $1.37 | $0.24 |
| 52 Week High | $2.95 | $1.43 |
Technical Indicators
Market Signals| Indicator | AWRE | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 45.49 |
| Support Level | $2.06 | $0.74 |
| Resistance Level | $2.17 | $0.83 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 31.58 | 9.86 |
Price Performance
Historical ComparisonAbout AWRE Aware Inc.
Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. The government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Its commercial applications include user authentication for login to mobile devices, computers, networks, and software programs, user authentication for financial transactions and purchases. Its geographical segments include the United States, the United Kingdom, and the Rest of the world, out of which it derives maximum revenue from United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.